Pulsed radiofrequency in lumbar radicular pain: clinical effects in various etiological groups.

BACKGROUND: The purpose of this study was to evaluate the effectiveness of pulsed radiofrequency (PRF) applied to the lumbar dorsal root ganglion (DRG). METHODS: A retrospective analysis of 54 consecutive patients who underwent 75 PRF procedures was performed. The patients were divided into three groups according to the etiology of the lesion (herniated disc [HD], spinal stenosis [SS], and failed back surgery syndrome [FBSS]). The analgesic efficacy of the technique was assessed using a 10-point Numeric Rating Scale (NRS) at baseline and, along with the Global Perceived Effect (GPE), at 30, 60, 90, and 180 days. The reduction in medications and the number of complications associated with the technique were assessed. RESULTS: A decrease in the NRS score was observed in patients with HD (P < 0.05) and SS (P < 0.001), but not in those with FBSS. The GPE scores confirmed this finding. No complications were noted. CONCLUSIONS: We observed that PRF of the DRG was significantly more efficacious in HD and SS than in FBSS patients. The application of PRF was not effective in FBSS.

Thermocoagulation of the ganglion impar or ganglion of Walther: description of a modified approach. Preliminary results in chronic, nononcological pain.

The ganglion impar, a single structure usually found at the anterior aspect of the sacrococcygeal joint, is the lowest ganglion of the paravertebral sympathetic chain. Its blockade is indicated in visceral pain syndromes and/or sympathetic pain syndromes of the perineal region. Several approaches to this block have been described, mainly through the anococcygeal or sacrococcygeal ligaments. We propose a modified approach to thermocoagulation of the ganglion impar, using a two-needle technique, the first one, placed through the sacrococcygeal ligament, the transsacrococcygeal needle, and the second one through a coccygeal disc, the transdiscal needle. The thermocoagulation technique that we employ uses a conventional radiofrequency application of 80 degrees C for 80 seconds through each needle. In this prospective study, 13 patients with chronic perineal, noncancer-related pain were followed for a maximum of 6 months. All of these patients underwent diagnostic ganglion impar block with local anesthetic prior to inducing neurodestruction with conventional radiofrequency application, as a positive result to the diagnostic local anesthetic block was a requisite for radiofrequency neurodestruction. We measured pain using a visual analog scale (VAS) before and after treatment. Statistical significance was assessed using the Mann-Whitney U-test and Wilcoxon range summation test. Initially the VAS was equal to or greater than 7. After therapy the VAS decreased by an average of 50% in the whole group. There were no adverse events. Our result show that this proposed modified approach to the block and use of radiofrequency for the ganglion impar is useful for the treatment of perineal noncancer-related pain.

The psychological assessment of candidates for spinal cord stimulation for chronic pain management.

It is known that, in spite of meeting appropriate clinical criteria for spinal cord stimulation (SCS) and having undergone flawless procedures, a significant number of patients who fail the therapy continues to exist. It is the purpose of this article to focus on the development of psychosocial indicators of success for SCS, if any. Referring to specialist literature authors present a review of what is known, what is not known, and what remains controversial on this topic. After reading this article we hope the reader will understand the importance of a psychological evaluation as part of the development of standards for identifying appropriate patients for this therapy. To improve treatment outcomes of SCS, seems to be essential to perform psychosocial evaluations on all persons clinically indicated for SCS to exclude those patients, who most probably, on a psychosocial level, will fail the procedure. To maximize treatment efficacy, authors believe spinal cord stimulation for chronic pain control must be part of a comprehensive program. An accurate preoperative psychosocial assessment and a course of psychological assistance both before and after therapy seems to be crucial for improving outcomes.

Continuous morphine infusion: a retrospective study of efficacy, safety, and demographic variables.

Objectives. This study aims to assess the efficacy of intrathecal infusion in different types of pain. A number of different variables were assessed to analyze their effect on therapy and to determine in which patients intrathecal infusion is more effective. Materials and Methods. A retrospective study was conducted with data obtained from 1983 to 2002. During this period, 292 intrathecal morphine tests were performed, with positive results in 205 cases. Eight nonprogrammable intrathecal pumps and 205 programmable pumps were implanted. One hundred and thirty-one programmable pumps were studied in which the drug used was morphine alone. Efficacy and side-effects were analyzed in the overall sample, depending on the type of pain, gender, age (20-40, 40-64, > 65), and dose of morphine used (< 2, 2-4.9, 5-14.9, > 15). Results. All results are expressed as median and interquartile range (p25-p75) because the data had a nonnormal distribution. The patients' mean age was 61 years (range 50-70 years); there were 61 men (46.6%) and 70 women (53.4%). The most commonly reported pain types were cancer pain (64, 48.9%), neuropathic pain (51, 38.9%), and nociceptive pain (16, 12.2%). Test dose used was 0.4 mg/day (0.2-0.7), and mean number of test days was 6 days (range 4-9 days). The initial morphine dose was 0.50 mg (0.30-1.45), mean dose was 2.70 mg (1.25-6.20), and the final dose was 4 mg (0.0-47). The initial numerical rating scale score of 8 (8,9) decreased to 4 (3-8) and 2 (1-5) at the end of the study. The overall rate of complications was 35.35%. Relief was very good in 29 (50.4%), good in 66 (22.1%), fair in 20 (15.3%), and poor in 16 (12.2%) patients. Univariate analysis. (Morphine): Gender: Male 49/58 (84.48%) vs. Female 43/65 (66.15%), RR 1.27 (1.04-1.57), p = 0.02 (chi-squared). No significant differences were found in the other variables studied (age and type of pain). The multivariate analysis (logistic regression analysis) revealed a significant difference with regard to gender, with an odds ratio of 2.78 in favor of male gender. When the efficacy and safety of the infusion was compared to the dose of morphine used, no significant differences were observed, with p = 0.65 for efficacy and p = 0.69 for safety. Conclusions. Pain relief was obtained with this technique in approximately 70% of patients, with no differences between pain types, but with a significant difference in favor of male gender.

Spinal cord stimulation: a 20-year retrospective analysis in 260 patients.

Introduction. Spinal cord stimulation (SCS) is used clinically by many pain physicians and neurosurgeons alike without regard to their own outcome data. Methods. We reviewed our 20-year experience retrospectively of patients receiving SCS implants and analyzed our data by pain type and group. Results. We present 260 patients, 140 men and 120 women. The most frequent type of pain in our series was neuropathic pain in 44.25% and the most frequent diagnosis was peripheral vascular disease (PVD) with 98 cases. The second was failed back surgery syndrome (FBSS) with 65 cases and the third was complex regional pain syndrome type I (CRPS I), with 40 cases. In CRPS group, the mean visual analog scale (VAS) of this group was 77.89 ± 13.38. In total, 5% had no pain relief, 40% had poor pain relief, 47.5% had good pain relief, and 7.5% had excellent pain relief. In FBSS group, the mean VAS was 79.62 ± 11.69 mm. A total of 13.80% had no pain relief at all, 35.39% had poor pain relief, 50.76% had good pain relief, and there were no patients in this group who had complete pain relief. A total of 98 patients, 78 men and 20 women, were diagnosed with PVD. The mean VAS of this group was 69.75 ± 14.36 mm. A total of 11.22% had poor pain relief, 87.75% had good pain relief. One patient had complete pain relief and all patients in this group perceived at least some improvement in their symptoms. The rate of complications was close to 28% in our overall sample. Conclusions. In conclusion, we demonstrated the utility over time of this type of treatment is comparable with other series of efficacy of SCS. The analgesic efficacy was close to 65% in the overall group. The therapy was not free of complications. The preponderance of our patients was patients with the diagnosis of PVD and our results in this group of patients were excellent. These excellent results of more than 90% improvement suggest to us that SCS be considered as a first-line approach to the clinical management of patients with pain and ulcer of PVD.

Analgesic efficacy of zoledronic acid and its effect on functional status of prostate cancer patients with metastasis.

OBJECTIVES: A multi-centered observational study evaluated the efficacy of zoledronic acid for improving pain and mobility, and preventing skeletal-related events (SRE) (fracture, spinal compression, pain-relieving radiotherapy), in patients with prostate cancer and bone metastasis. MATERIALS AND METHODS: Males (n = 218) with prostate cancer and bone metastasis undergoing oncologic therapy received zoledronic acid (4 mg iv/month) for 6 months. Parameters evaluated were: 1) pain and movement after 2 consecutive doses; 2) quality of life; 3) SRE incidence and time-to-appearance. Medication tolerance and treatment satisfaction were assessed using a questionnaire. RESULTS: A total of 170 that matched all the inclusion criteria (78%) out of 218 were evaluable for efficacy. There was a measurable statistically significant reduction in pain at rest and on movement as well as an improvement in the quality of life compared with baseline. Best results were obtained with early treatment. Overall incidence of bone events was 11.2%. Of the 212 patients (97.2%) evaluable for safety, 16% suffered adverse events and 66% expressed satisfaction with the treatment DISCUSSION: Zoledronic acid is effective for reducing pain, improving mobility, and increasing the quality of life in patients with prostate cancer with bone metastasis. Its easy administration and good tolerability make zoledronic acid one of the principal therapeutic tools in the management of patients with pain associated with bone metastasis from prostate cancer.

Dual spinal cord stimulation for complex pain: preliminary study.

Objectives To retrospectively analyze by indices of success, patients with chronic complex pain, including, axial low back pain, receiving dual spinal cord stimulation (SCS) systems. Methods Eighteen patients with dual spinal cord stimulators have been retrospectively and nonrandomly analyzed. The preponderance of patients in our study group had failed back surgery syndrome (FBSS). Parameters of success of our therapy included reduction of medication, if any, complications, if any, and satisfaction with therapy and improvement in the quality of life, measured by a visual analogical scale (VAS) from 0 to 10. Patients were asked to rate their overall experience with their SCS systems and were divided into four separate groupings according to their overall rating of their therapy. These four groupings included therapy ratings of excellent (70-100%), good (> 50%), fair (< 50%), and poor (< 30%). Satisfaction with therapy and improvement in quality of life were evaluated on a five-point scale. Patients were asked to rate changes in their quality of life after therapy using the following normative scale: much better, better, no change, worse, and much worse. All the patients in our study were asked if they would repeat their therapy with dual spinal cord stimulation. Results Paresthesia coverage, overlapping the reported painful region, was obtained in 80% of the patients in our study. The VAS decreased an average of 5.6 (range 2-10) after 6 months and 4.9 (range 2-8) at the end of the study. Six patients (37.5%) reported excellent results; four patients (25%) reported good; three (18.7%), fair and poor. Seventy percent of the patients were satisfied with the treatment and reported an increase in their quality of life. Medications were reduced in 75% of the patients. Thirteen (81%) patients with dual lead SCS therapy were willing to repeat the SCS implant procedure. Complications occurred in 43.7%. Conclusions Dual spinal cord stimulation is appropriate and efficacious for treating complex pathology and complex pain that including pain of the low, axial back.